Sarepta Therapeutics, Inc. Forecast, price target & analysts
Sarepta Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Sarepta Therapeutics, Inc. Classifications & Recommendation:
Sarepta Therapeutics, Inc. Price Target
| Target Price | $149.83 |
| Price | $61.51 |
| Potential |
143.58%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .
The average Sarepta Therapeutics, Inc. target price is $149.83.
This is
143.58%
register free of charge
$209.00
239.78%
register free of charge
$70.00
13.80%
register free of charge
|
|
| A rating was issued by 25 analysts: 21 Analysts recommend Sarepta Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of
143.58%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.90 | 3.05 |
| 52.97% | 60.18% | |
| EBITDA Margin | 14.30% | 24.76% |
| 185.10% | 73.16% | |
| Net Margin | 11.92% | 11.80% |
| 126.37% | 1.02% |
22 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.34 | 3.71 |
| 140.34% | 58.55% | |
| P/E | 16.57 | |
| EV/Sales | 1.96 |
15 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Current Sarepta Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 04 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Apr 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 04 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 03 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
